Rehart Insurance Reimbursement Price Determination ｜ July 22, 2026

Performance Overview

Qualips announced that the Central Social Insurance Medical Council approved the insurance reimbursement price of 53,200,000 yen for the human (allogeneic) iPS cell-derived cardiac muscle cell sheet RehartⓇ, which received conditional and time-limited manufacturing and marketing approval in March 2026. The insurance listing is scheduled for September 1, 2026, enabling domestic sales to commence. There has been considerable inquiry from overseas, and efforts toward global expansion are underway.

Future Outlook and Impact

Following the insurance listing, sales of RehartⓇ are expected to begin, with a forecast of increased treatment demand domestically and internationally. The specific impact on consolidated results for the fiscal year ending March 2027 is currently under review; however, plans include expanding treatment offerings for patients with severe heart failure while also considering overseas expansion.